Erratum: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192)

Renata Ferrarotto; Yoshitsugu Mitani; Daniel James McGrail; Kaiyi Li; Tatiana V Karpinets; Diana Bell; Steven Jay Frank; Xingzhi Song; Michael Elliot Kupferman; Bin Liu; J. Jack Lee; Bonnie S Glisson; Jianhua Zhang; Jon C. Aster; Shiaw Yih Lin; P. Andrew Futreal; John Victor Heymach; Adel K El-Naggar

doi:10.1158/1078-0432.CCR-23-1697

Erratum: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192)

Renata Ferrarotto, Yoshitsugu Mitani, Daniel James McGrail, Kaiyi Li, Tatiana V Karpinets, Diana Bell, Steven Jay Frank, Xingzhi Song, Michael Elliot Kupferman, Bin Liu, J. Jack Lee, Bonnie S Glisson, Jianhua Zhang, Jon C. Aster, Shiaw Yih Lin, P. Andrew Futreal, John Victor Heymach, Adel K El-Naggar

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original version of this article (1), the Methods section contained two inaccuracies: MYC scoring was stated to be binary (positive, negative) when it was tertiary (high, low, negative), and the positive/negative benchmark for TP63 expression was stated to be at 70% of cells when it was at 10% of cells. The errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret the errors.

Original language	English (US)
Pages (from-to)	2737
Number of pages	1
Journal	Clinical Cancer Research
Volume	29
Issue number	14
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-1697
State	Published - Jul 2023

ASJC Scopus subject areas

General Medicine

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1158/1078-0432.CCR-23-1697

Fingerprint

Dive into the research topics of 'Erratum: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192)'. Together they form a unique fingerprint.

Cite this

Ferrarotto, R., Mitani, Y., McGrail, D. J., Li, K., Karpinets, T. V., Bell, D., Frank, S. J., Song, X., Kupferman, M. E., Liu, B., Lee, J. J., Glisson, B. S., Zhang, J., Aster, J. C., Lin, S. Y., Futreal, P. A., Heymach, J. V., & El-Naggar, A. K. (2023). Erratum: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192). Clinical Cancer Research, 29(14), 2737. https://doi.org/10.1158/1078-0432.CCR-23-1697

Erratum: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192). / Ferrarotto, Renata; Mitani, Yoshitsugu; McGrail, Daniel James et al.
In: Clinical Cancer Research, Vol. 29, No. 14, 07.2023, p. 2737.

Research output: Contribution to journal › Comment/debate › peer-review

Ferrarotto, R, Mitani, Y, McGrail, DJ, Li, K , Karpinets, TV, Bell, D, Frank, SJ, Song, X, Kupferman, ME, Liu, B, Lee, JJ, Glisson, BS, Zhang, J, Aster, JC, Lin, SY, Futreal, PA , Heymach, JV & El-Naggar, AK 2023, 'Erratum: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192)', Clinical Cancer Research, vol. 29, no. 14, pp. 2737. https://doi.org/10.1158/1078-0432.CCR-23-1697

@article{eb2cea6ffebb4dba8a21d3cbed0f22f1,

title = "Erratum: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192)",

abstract = "In the original version of this article (1), the Methods section contained two inaccuracies: MYC scoring was stated to be binary (positive, negative) when it was tertiary (high, low, negative), and the positive/negative benchmark for TP63 expression was stated to be at 70% of cells when it was at 10% of cells. The errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret the errors.",

author = "Renata Ferrarotto and Yoshitsugu Mitani and McGrail, {Daniel James} and Kaiyi Li and Karpinets, {Tatiana V} and Diana Bell and Frank, {Steven Jay} and Xingzhi Song and Kupferman, {Michael Elliot} and Bin Liu and Lee, {J. Jack} and Glisson, {Bonnie S} and Jianhua Zhang and Aster, {Jon C.} and Lin, {Shiaw Yih} and Futreal, {P. Andrew} and Heymach, {John Victor} and El-Naggar, {Adel K}",

note = "Publisher Copyright: {\textcopyright} 2023 American Association for Cancer Research.",

year = "2023",

month = jul,

doi = "10.1158/1078-0432.CCR-23-1697",

language = "English (US)",

volume = "29",

pages = "2737",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "14",

}

TY - JOUR

T1 - Erratum

T2 - Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192)

AU - Ferrarotto, Renata

AU - Mitani, Yoshitsugu

AU - McGrail, Daniel James

AU - Li, Kaiyi

AU - Karpinets, Tatiana V

AU - Bell, Diana

AU - Frank, Steven Jay

AU - Song, Xingzhi

AU - Kupferman, Michael Elliot

AU - Liu, Bin

AU - Lee, J. Jack

AU - Glisson, Bonnie S

AU - Zhang, Jianhua

AU - Aster, Jon C.

AU - Lin, Shiaw Yih

AU - Futreal, P. Andrew

AU - Heymach, John Victor

AU - El-Naggar, Adel K

PY - 2023/7

Y1 - 2023/7

N2 - In the original version of this article (1), the Methods section contained two inaccuracies: MYC scoring was stated to be binary (positive, negative) when it was tertiary (high, low, negative), and the positive/negative benchmark for TP63 expression was stated to be at 70% of cells when it was at 10% of cells. The errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret the errors.

AB - In the original version of this article (1), the Methods section contained two inaccuracies: MYC scoring was stated to be binary (positive, negative) when it was tertiary (high, low, negative), and the positive/negative benchmark for TP63 expression was stated to be at 70% of cells when it was at 10% of cells. The errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret the errors.

UR - http://www.scopus.com/inward/record.url?scp=85164754133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164754133&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-23-1697

DO - 10.1158/1078-0432.CCR-23-1697

M3 - Comment/debate

C2 - 37449360

AN - SCOPUS:85164754133

SN - 1078-0432

VL - 29

SP - 2737

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 14

ER -

Erratum: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets (Clinical Cancer Research (2021) 27 (852–64) DOI: 10.1158/1078-0432.CCR-20-1192)

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this